Similarly, enhanced expression of hepatic miR-27a alleviated the development of NAFLD in obese mice through inhibiting Fasn and Scd1 expression and hepatic lipogenesis (Fig. 4). This evidence concerns the gene FASN and metabolic dysfunction-associated steatotic liver disease.